Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Ciaccia, D.
space
  arrow  Gress, F. G.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

LETTER

Somatostatin Receptor Scintigraphy in the Zollinger-Ellison Syndrome

right arrow Donato Ciaccia, MD, and Frank G. Gress, MD

1 May 1997 | Volume 126 Issue 9 | Page 741


TO THE EDITOR:

We read with great interest the article by Gibril and coworkers [1] on the use of somatostatin receptor scintigraphy (SRS) for the detection of primary and metastatic gastrinomas in patients with the Zollinger-Ellison syndrome. The authors report a 58% sensitivity for diagnosing primary gastrinomas; this sensitivity was much higher than those of other methods-computed tomography, magnetic resonance imaging, angiography, and transabdominal ultrasonography.

However, we were surprised by the authors' failure to mention endoscopic ultrasonography (EUS) as the foremost diagnostic method for the localization of functioning islet cell tumors. The sensitivity of EUS for localization of hormonally active islet cell tumors has ranged from 57% to 100%, with a cumulative sensitivity of approximately 80% [2, 3]. In the diagnosis of primary gastrinomas, EUS has a reported sensitivity of 86% [4]. It can also detect local regional adenopathy. The downside is that EUS cannot adequately visualize the right lobe of the liver, and it is not useful for the detection of distant metastases other than those to the liver.

In addition, the advent of EUS-guided fine-needle aspiration biopsy [5] now allows localization, staging, and direct cytologic confirmation of suspected neuroendocrine tumors (Ciaccia D, Gress FG. Unpublished data). In academic health centers, where patients suspected of having active neuroendocrine tumors might be referred, EUS is becoming more widely available. Both the accuracy and availability of EUS should prompt physicians to consider it as the first diagnostic study in patients suspected of having a hormonally active islet cell tumor that is not metastatic. A study comparing SRS and EUS as diagnostic methods for the localization of islet cell tumors is needed. The omission of this information seriously detracts from what is otherwise an important paper in the management of gastrinomas and other islet cell tumors.


Author and Article Information
space
up arrowTop
dotAuthor & Article Info
down arrowReferences

Indiana University Medical Center, Indianapolis, IN 46202


References
space
up arrowTop
up arrowAuthor & Article Info
dotReferences

1. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann Intern Med. 1996; 125:26-34.

2. Rosch T, Lightdale C, Botet J, Boyce G, Sivak M, Yasuda K, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med. 1992; 326:1721-6.

3. Rosch T, Classen M. Pancreatic endocrine tumors. In: Gastroenterologic Endosonography: Textbook and Atlas. New York: Thieme Medical Publishers; 1992:134-9.

4. Ruszniewski P, Amouyal P, Amouyal G, Grange JD, Mignon M, Bouche O, et al. Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery. 1995; 117:629-35.

5. Chang KJ, Katz KD, Durbin TE, Erickson RA, Butler JA, Lin F, et al. Endoscopic ultrasound-guided fine-needle aspiration. Gastrointest Endosc. 1994; 40:694-9.

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.





box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Ciaccia, D.
space
  arrow  Gress, F. G.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online